P rotein prenylation comprises a class of irreversible post-translational modification predicted to affect hundreds of proteins in the human proteome 1 . Farnesyl transferase (FTase) and geranylgeranyl transferase type 1 (GGTase-1) catalyse attachment of a single farnesyl or geranylgeranyl isoprenoid to a canonical C-terminal CXXX-motif (C = Cys; X = any amino acid) on proteins including Ras and Rho GTPases, nuclear lamins and gamma subunits of heterotrimeric G-proteins (Fig. 1a) . RabGGTase (GGTase-2) attaches one or two geranylgeranyl chains to members of the Rab family at a variety of cysteine-containing C-terminal motifs, with the assistance of Rab escort proteins, REP-1 or REP-2. Prenylation plays an important role in all normal cells, and in numerous human pathologies including cancers , diseases in which FTI efficacy is thought to occur mainly through a specific prenylated protein. To explain past failures and set future directions there is a need to understand the prenylated proteome in specific cellular contexts and to determine which proteins are targeted by inhibition of each prenyl transferase 2 . Chemical proteomics is a powerful methodology to decipher substrates of post-translational modifications (PTMs), particularly for analytically challenging PTMs such as lipidation [8] [9] [10] . Several useful chemical probes for protein prenylation have been reported [11] [12] [13] [14] [15] [16] , but currently available methodologies provide limited coverage of the prenylated proteome and poor selectivity for farnesylation versus geranylgeranylation pathways. There thus remains a need for chemical probes that can enable high-throughput quantification of specific changes in prenylation in disease models or in response to PTIs, at the whole proteome level.
These authors contributed equally: Elisabeth M. Storck, Julia Morales-Sanfrutos. *e-mail: e.tate@imperial.ac.uk P rotein prenylation comprises a class of irreversible post-translational modification predicted to affect hundreds of proteins in the human proteome 1 . Farnesyl transferase (FTase) and geranylgeranyl transferase type 1 (GGTase-1) catalyse attachment of a single farnesyl or geranylgeranyl isoprenoid to a canonical C-terminal CXXX-motif (C = Cys; X = any amino acid) on proteins including Ras and Rho GTPases, nuclear lamins and gamma subunits of heterotrimeric G-proteins (Fig. 1a) . RabGGTase (GGTase-2) attaches one or two geranylgeranyl chains to members of the Rab family at a variety of cysteine-containing C-terminal motifs, with the assistance of Rab escort proteins, REP-1 or REP-2. Prenylation plays an important role in all normal cells, and in numerous human pathologies including cancers 2 , cardiovascular 3 and retinal 4 diseases, viral infections 5, 6 and Hutchinson-Gilford progeria syndrome (HGPS) 7 . Prenyl transferase inhibitors (PTIs) have been proposed as inhibitors of Ras signalling in cancer, but, despite extensive clinical trials, none of these agents have yet been approved for clinical use 2 . Further development is hampered by limited validation of the cellular targets of prenylation and poor understanding of the dynamic interplay between prenyl transferases and their substrates in response to inhibition, which can drive certain substrates to 'switch' between farnesylation and geranylgeranylation, making patient selection highly challenging 1 . Recently, farnesyl transferase inhibitors (FTIs) have shown positive clinical results in HGPS 7 and chronic hepatitis delta virus infection 6 , diseases in which FTI efficacy is thought to occur mainly through a specific prenylated protein. To explain past failures and set future directions there is a need to understand the prenylated proteome in specific cellular contexts and to determine which proteins are targeted by inhibition of each prenyl transferase 2 . Chemical proteomics is a powerful methodology to decipher substrates of post-translational modifications (PTMs), particularly for analytically challenging PTMs such as lipidation [8] [9] [10] . Several useful chemical probes for protein prenylation have been reported [11] [12] [13] [14] [15] [16] , but currently available methodologies provide limited coverage of the prenylated proteome and poor selectivity for farnesylation versus geranylgeranylation pathways. There thus remains a need for chemical probes that can enable high-throughput quantification of specific changes in prenylation in disease models or in response to PTIs, at the whole proteome level.
Here, we report a high-throughput approach for the exploration of protein prenylation in living cells, exploiting a pair of novel alkyne-tagged prenyl probes coupled with multifunctional capture reagents and a quantitative chemical proteomics workflow (Fig. 1b) . We demonstrate that this methodology can be used to identify novel prenylated proteins at a proteome-wide scale and at endogenous cellular abundance, as well as to quantify substrate-specific inhibition of prenylation upon treatment with different classes of PTIs, enabling system-level validation and invalidation of widely used tool inhibitors. We further show the broad utility of these probes to quantify 'rescue' prenylation induced by treatment with a potent FTI, directly identify post-translational processing of prenylated C termini, and quantify the complex effect on geranylgeranylation resulting from REP-1 knockout in a model of the X-linked retinal disease choroideremia. Together, these probes and capture reagents significantly extend the existing tools available for metabolic prenyl labelling (Supplementary Table 1) , enabling new applications in the exploration of protein prenylation in living cells.
Results
Novel alkyne-tagged isoprenoid analogues YnF and YnGG enable identification and quantification of prenylated proteins. We reasoned that structural similarity of chemical probes to the natural products farnesol (FOH) and geranylgeraniol (GGOH) should lead to high-fidelity incorporation into cellular prenylated targets. Accordingly, we developed two prenyl probes designed to target farnesylation and geranylgeranylation selectively, termed YnF and YnGG, respectively ( Fig. 1b; for the synthetic methodology see Supplementary Information), in which an alkyne moiety enables post-incorporation coupling of functional 'capture reagents' bearing fluorophores and/or affinity tags through copper(i)-catalysed azidealkyne cycloaddition (CuAAC) (so-called 'click') chemistry 17, 18 . 
Fig
. 1 | Global labelling of prenylated proteins using novel alkyne-tagged isoprenoid analogues. a, Prenylation, the covalent attachment of a farnesyl or geranylgeranyl isoprenoid to a cysteine near the protein C terminus, is catalysed by FTase or GGTase-1 on proteins bearing a C-terminal CXXX motif (C = Cys; X = any amino acid) or by RabGGTase at the C terminus of Rab proteins. Some CXXX proteins undergo further processing by RCE-1 (cleavage of the C-terminal -XXX residues) and isoprenylcysteine carboxyl methyltransferase (ICMT) (carboxyl methylation). b,c, Schematic of metabolic labelling workflow by novel alkyne-tagged prenyl probes YnF and YnGG (b). Probe-labelled proteins can be processed by Cu(i)-catalysed click chemistry to attach capture reagents with various functionality such as affinity tags or fluorophores to enable enrichment for mass spectrometric analysis or visualization by in-gel fluorescence (c) in EA.hy926 cells.
The corresponding pyrophosphates of each probe (YnFPP and YnGGPP, Supplementary Fig. 1 ) were also synthesized, and their incorporation into peptides mimicking prenylated protein substrate C termini was compared against FPP and GGPP, for FTase and GGTase-1 ( Supplementary Fig. 1 ), using a biochemical enzyme assay (see Supplementary Information). In line with the biomimetic design of the probes, transfer of each probe was found to exhibit rates of incorporation and the Michaelis constant (K m ) values aligned with those of the canonical native prenyl pyrophosphate for FTase (RHEB) and GGTase-1 (RHOA) peptide substrates, with no cross-reactivity with the non-substrate peptide/transferase pair ( Supplementary Fig. 2 ). Probe incorporation in cells was first examined in an endothelial cell line (EA.hy926 19 ), adding YnF or YnGG at a range of concentrations to cells in culture over 24 h, followed by isolation of protein and ligation by CuAAC to AzTB, an azide-tagged capture reagent bearing a TAMRA fluorophore and a biotin handle 18 . Analysis by ingel fluorescence showed excellent incorporation of the probes at low micromolar concentration, with labelling evident at 1 µM probe, and increasing at 10 µM (Fig. 1c) . Previous studies using prenyl probes have typically pretreated cells with a HMG-CoA reductase inhibitor (statin) to deplete endogenous isoprenoids and enhance labelling 11, 15, 16 ; however, statins exert widespread effects on metabolism, including changes in the levels of cholesterol metabolites and of prenylated proteins 20 . In contrast, incorporation of YnF and YnGG proceeds with high efficiency without statin treatment, enabling the study of prenylation under unperturbed conditions. Both probes showed strong labelling in the 20-25 kDa region by in-gel fluorescence, consistent with labelling of small GTPases, but each probe also labelled an orthogonal set of bands, suggesting that selective farnesyl and geranylgeranyl probes may provide enhanced coverage of the whole complement of prenylated proteins. Consistent with selective labelling, probe incorporation was sensitive to competition by the respective natural isoprenoid substrate, farnesol (FOH) or geranylgeraniol (GGOH) (Supplementary Fig. 3) .
We next employed a quantitative chemical proteomics strategy to identify and validate protein targets labelled by the probes, using competition against natural isoprenoids. EA.hy926 cells were treated with 10 µM YnF or YnGG in the presence of increasing concentrations of FOH (0, 5 and 25 µM) or GGOH (0, 2.5 and 10 µM), and cell lysates spiked SILAC (stable isotope labeling by/with amino acids in cell culture) lysate dual-labelled with N 2 -Lys (R10K8) and the relevant prenyl probe, providing a mass standard against which competition could be quantified 21 . Following CuAAC ligation, affinity enrichment and on-bead tryptic digest, samples were analysed by nano liquid chromatography-tandem mass spectrometry (nanoLC-MS/MS) on a high-resolution Orbitrap mass spectrometer ( Supplementary Data 1 and 2) . Although some overlap in protein identification between the two probes was evident, 75% of proteins that significantly responded to competition were uniquely detected by one probe only ( Supplementary Fig. 3 ), underlining the advantages of a dual farnesyl and geranylgeranyl probe system. All proteins sensitive to competition by natural isoprenoids carried a potential prenylation motif, with the exception of four proteins known to interact with Rabs (COPA, CD9, CD151 and PODXL), enabling robust identification of prenylated proteins over background (Fig. 2a,b, Supplementary Fig. 4 and Supplementary  Data 1 and 2) . The probes discriminate with high selectivity between known non-prenylated or prenylated proteins, with only the latter showing significant changes in the presence of competing canonical substrate (FOH or GGOH). YnF also identified seven novel farnesylated proteins that showed identical competition behaviour to the set of known farnesylated proteins (Fig. 2a) : serine-threonine kinase ULK3, DDB1-and CUL4-associated factor 8 (DCAF8/ WDR42A), centrosomal protein CEP85, leucine-rich repeat protein LRRFIP1, nuclear assembly protein NAP1L4, RhoBTB subfamily member RHOBTB3, and protein DPCD. Our approach also enables objective identification of CXXX motif proteins which are not substrates for probe incorporation (Fig. 2a,b ). For example, ubiquitin C-terminal hydrolase L1 (UCHL1), an abundant deubiquitinase previously reported to be farnesylated 22 , was not identified as a substrate for either probe in EA.hy926 cells. A UCHL1 C-terminal peptide was also not a substrate for prenylation in biochemical assays with any prenyl pyrophosphate (FPP, YnFPP, GGPP or YnGGPP; Supplementary Fig. 2 ). Of the 80 prenylated proteins identified here with high confidence, 64 are shown to be prenylated at endogenous cellular abundance for the first time, without the use of disruptive protein overexpression or treatment with a statin (Supplementary Data 1), thus providing the most comprehensive set of prenylated proteins for a single cell type determined so far. A further three putative farnesylated and six putative geranylgeranylated proteins were identified for which competition resulted in non-detection of the protein even at the lowest concentration of natural isoprenoid (Supplementary Data 1, 'low confidence' substrates).
Competition experiments are widely used in chemical proteomic analyses to differentiate between selective labelling and nonspecific pulldown (for example due to interaction with the affinity resin) 17, 23, 24 ; however, these data do not differentiate between competition at the levels of pyrophosphate biosynthesis or transferase recognition. We therefore further probed concentration-dependent probe incorporation into farnesylated and geranylgeranylated substrates in cells in the absence of competing FOH or GGOH, comparing incorporation in cells treated with 1, 2, 5 or 10 µM YnF or YnGG using a 10-plex tandem mass tag (TMT10) methodology to enable relative quantification between all concentrations across both probes, and against a vehicle 5 ). These data mirror the biochemical selectivity of the probes, and further support transferase-selective incorporation of each probe in cells.
Validation of known and novel substrates was performed by affinity enrichment of labelled proteins followed by immunoblot analysis, and mirrored the results obtained in the proteomics analysis. Known farnesylated protein HRAS and novel target ULK3 were preferentially labelled by YnF, known geranylgeranylated proteins (RHOA, RAB8A and RAB22A) preferentially incorporated YnGG (Fig. 2c) , and labelling was sensitive to competition with the relevant natural isoprenoid. Furthermore, ULK3 and CEP85 mutants in which the CXXX cysteine was mutated to serine or alanine (CS and CA mutants) were not labelled by YnF, confirming that probe modification is dependent on the predicted site of prenylation (Fig. 2d) .
We next confirmed that the probes are effective in a range of different cell types, including cervical cancer (HeLa), breast cancer (MCF7) and monocytes (THP1). In each case and for each probe, labelling could be readily observed, without addition of statin, at concentrations from 1 to 10 µM, although with some variations in apparent efficiency of incorporation ( Supplementary  Fig. 6 ). Selectivity towards farnesylated (ULK3) and geranylgeranylated (RHOA) substrates was maintained across all cell types, as demonstrated by affinity enrichment and immunoblot analyses ( Supplementary Fig. 7 ).
YnF and YnGG enable direct detection of prenylation by mass spectrometry. Direct detection of the site of protein lipidation by mass spectrometry is notoriously challenging, and a general proteome-wide approach has not been reported for protein prenylation, which for many substrates is further complicated by a cascade of post-translational proteolysis and methylation (Fig. 1a) . Building on our previous demonstration of direct identification of protein myristoylation using multifunctional capture reagents 17, 18, 25 , we employed AzRB, AzRTB and Az3MRB 18 ( Supplementary Fig. 8 ) for the direct analysis of protein prenylation. Each of these reagents harbours an enzyme-cleavable sequence to enhance the release and detection of modified peptides upon protein digestion with trypsin, or lysarginase, a thermophilic proteinase that can enhance the identification of C-terminal peptides 26 ( Fig. 3a) . Analysis of the MS/MS spectra of identified YnF-and YnGG-modified peptides revealed characteristic C-S bond scission marker ions analogous to canonical prenylated peptides (Supplementary Figs. 9 and 10) 27 , and cross-validation against orthogonal marker ions from each capture reagent enabled robust sequence assignment (Fig. 3b) .
The 26 distinct prenylated peptides identified in our analysis ( Fig. 3c and Supplementary Data 4) mapped to the C-terminal CXXX motif of one of 18 distinct proteins, including both wellestablished prenylated substrates (for example, nuclear lamins, Rho and Ras protein family members) and novel prenylated proteins ULK3, DCAF8 and NAP1L4. Twelve peptides had undergone C-terminal hydrolytic cleavage, generating a prenylated C-terminal cysteine, a further four peptides were cleaved and methylated, and the remaining 10 featured unprocessed C termini (Supplementary Data 4) . These findings demonstrate that YnF and YnGG labelling is compatible with endogenous post-prenylation processing by Ras-converting enzyme 1 (RCE1) and isoprenyl- cysteine carboxyl methyltransferase 28 . Interestingly, we also found strong evidence for novel C-terminal processing of geranylgeranylated RAB3B, RAB3D and RAB7A, in which the two terminal amino acids of the canonical XCXC motif have been removed (Supplementary Fig. 10 ). Taken together, these data provide the first example of direct identification of numerous prenylated and processed prenylation sites at endogenous abundance, at the whole proteome level. Chemical proteomics enables proteome-wide quantification of protein prenylation in response to prenyl transferase inhibition. As noted above, intense effort has been put into the development of inhibitors of prenyltransferases and enzymes involved in biosynthesis or processing steps up-or downstream of protein prenylation 1, 2 . However, inconsistent efficacy in clinical trials 2 suggests that the mode of action of PTIs is more complex than initially supposed, and the selectivity and impact of these inhibitors on prenylation has not been explored at the whole proteome level. We used YnF and YnGG to compare and quantify changes in prenylation in response to perturbation by four tool compounds widely used in cell and animal studies: FTI-277 (a FTase inhibitor) 29 and GGTI-2133 (a GGTase-I inhibitor), the natural product manumycin A (reported to be an inhibitor of FTase) 30 and the drug tipifarnib 31 , which is representative of subnanomolar potency FTIs that have entered over 30 clinical trials 2 . EA.hy926 cells were labelled with probe in the presence of increasing concentrations of PTI, and analysed and quantified using spike-in SILAC methodology.
Consistent with their known potencies, the FTase inhibitors tipifarnib and FTI-277 exhibited low nanomolar and micromolar mean in-cell half-maximum inhibitory concentration (IC 50 ) responses, respectively (Fig. 4a,b) . Quantitative chemical proteomics enabled dose-response relationships to be determined for each individual FTase substrate in the cell, revealing a wide range in estimated IC 50 . Notably, all novel farnesylated proteins identified above responded to farnesyltransferase inhibitors, further validating them as bona fide FTase substrates (Fig. 4b and Supplementary Data 1 and 5) , and immunoblot analyses of HRAS, ULK3 and DCAF8 confirmed that YnF labelling of all three proteins is sensitive to tipifarnib ( Supplementary Fig. 11 ). In contrast, there was no evidence that manumycin A impacted farnesylation up to the highest concentration tested (10 µM; Fig. 4c and Supplementary Data 5); acute cell toxicity was evident above this concentration (data not shown), strongly suggesting that phenotypes previously observed with this compound are unlikely to be directly related to prenylation and may be due to off-target effects and/or cytotoxicity. YnGG was similarly used to interrogate the effect of GGTase-1 inhibitor GGTI-2133 ( Fig. 4d and Supplementary Data 6) , providing an in-cell dose response for 14 known geranylgeranylated proteins. for both FTase and GGTase-1 under physiological conditions, or to switch to GGTase-1 upon inhibition of FTase 1 (Fig. 5a ). We used our two-probe system to explore the balance between farnesylation and geranylgeranylation in the unperturbed cellular environment and in response to FTI treatment. Spiking lysates with a reference sample labelled with R10K8 and both prenyl probes enabled a relative quantification of probe preference, confirming strong preferential incorporation of YnF or YnGG into farnesylated and geranylgeranylated substrates, respectively ( Fig. 5b and Supplementary  Fig. 12 ). Interestingly, RRAS2 was found to be prenylated by both probes, consistent with the observation that recombinant RRAS2 is an FTase and GGTase-1 substrate in vitro 32 .
YnF and
Having established a method to quantify the relative levels of probe incorporation we interrogated the dynamics of prenylation in response to PTI treatment. The failure in the clinic of FTIs as anticancer agents has been attributed in part to 'rescue prenylation' by GGTase-1 of substrates such as KRAS and NRAS 1, 2 . However, the prevalence of alternative prenylation of proteins other than the Ras isoforms remains largely unexplored, despite its potentially important impact on the clinical efficacy and tolerability of FTIs. We compared proteome-wide changes in the ratio of YnF/YnGG incorporation to inhibition of YnF labelling in response to treatment with the clinically relevant FTI tipifarnib over a range of inhibitor concentrations (Fig. 5c, Supplementary Fig. 12 and Supplementary Data 7). KRAS, NRAS and RRAS2 displayed robust dose-dependent increases in YnGG labelling, with a maximum effect evident at 10, 5 and 1 nM tipifarnib, respectively. The increase in YnGG incorporation mirrored the dose-dependent decrease in YnF labelling over the same concentration range (Fig. 5c) , indicating switch-like behaviour for these three proteins on treatment with an FTI. The previously identified robust response of RRAS2 YnGG labelling to GGTI-2133 (Fig. 4d) further suggests that this protein is prenylated by both FTase and GGTase-1 in cells, and it appears that inhibition of FTase can shift this balance towards geranylgeranylation. Remarkably, no other farnesylated protein showed a significant or robust response to inhibition ( Supplementary Fig. 12 and Supplementary Data 7) , demonstrating for the first time that rescue prenylation is restricted to a small set of specific proteins at the whole proteome level.
YnGG quantifies reduced geranylgeranylation of a specific subset of Rab proteins in a REP-1 knockout model of choroideremia.
Choroideremia is an X-linked genetic disease caused by loss-offunction mutations in the CHM gene, which encodes Rab escort protein 1 (REP-1) 4, 33 . Loss of REP-1 function affects approximately 1 in 50,000 people and causes degeneration of the choroid, retinal pigment epithelium and photoreceptors, leading to gradual loss of vision in affected patients 34 . REP-2 is apparently unable to compensate for loss of REP-1 in the eye 35 , and ongoing gene therapy trials aim to prevent loss of vision by adding functional CHM cDNA 36, 37 . REP proteins are required for prenylation by RabGGTase, and loss of REP-1 results in accumulation of non-prenylated Rab proteins (Fig. 6a) . However, the quantitative impact on Rab protein prenylation at the whole proteome level in a disease-relevant model remains unknown.
To interrogate which Rab substrates are most dependent on REP-1 for efficient prenylation, we applied YnGG to quantify differences in Rab geranylgeranylation levels in mouse embryonic fibroblasts (MEFs) derived from the conditional mouse Rep-1 knockout model of choroideremia 38 . Note that here, as elsewhere, by convention gene/protein names are in lower case for mouse (for example, Rep-1) and upper case for human (REP-1). Rep-1 knockout (FLOX TM) or control (FLOX) MEFs were incubated with YnGG (10 µM, 24 h) and the resultant lysate was spiked with a heavy standard generated from MEF cell line NIH 3T3 labelled with both R10K8 and YnGG, and processed for quantitative proteomic analysis as described above to generate relative quantification of changes in prenylation across 29 Rab proteins in Rep-1 knockout cells versus wild-type control (Fig. 6b, Supplementary  Fig. 13 and Supplementary Data 8) . The prenylation of 10 Rab proteins was significantly reduced upon Rep-1 knockout, with prenylation of Rab12 and 27b reduced to 10% and 24%, respectively, of the level observed in Rep-1 functional cells. As expected, YnGG incorporation into GGTase-1 substrates was largely unaffected by Rep-1 knockout (Supplementary Fig. 13 ). Protein levels in whole cell lysates were further quantified by proteomics ( Supplementary   Fig. 14) , demonstrating no significant changes in the expression of Rabs or CXXX substrate proteins, including Rab7a, 5c and 21, each of which showed significantly reduced levels of prenylation in Rep-1 knockout cells. Immunoblot analysis of Rab22a, Rab7 and a GGTase-1 substrate (RhoA) recapitulated the results obtained through quantitative proteomics, confirming that only Rab7 YnGG labelling is affected by Rep-1 knockout, with no changes in overall expression ( Fig. 6c and Supplementary Fig. 13 ).
Discussion
In this study we present a methodological approach to identify and quantify protein prenylation using a combination of alkyne-tagged prenylation probes and quantitative proteomics. Novel prenyl probes YnF and YnGG show preferential incorporation into farnesylated and geranylgeranylated proteins, respectively, maintaining selectivity for each transferase by mimicking overall chain length and hydrophobicity. Previous studies using prenyl analogues that depart significantly from the native lipid structure (for example, by direct integration of a fluorophore or branching in the isoprenoid chain) have variously reported negligible 13 or significant 39 impact on the biochemical efficiency of transfer to specific peptide or protein substrates, although these studies did not explore incorporation in a cellular setting. Here, we have presented multiple lines of evidence supporting transferase selectivity and substrate fidelity of YnF and YnGG, including enzyme kinetics, whole-proteome competition and concentration-dependent incorporation in cells for known and predicted farnesylated or geranylgeranylated proteins, cross-confirmation for known and novel substrates by immunoblot analyses in a range of cell lines, dose-dependent responses to selective FTase and GGTase-1 inhibitors including recapitulation of known prenyl switch responses, and direct mass spectrometric detection of specific probe incorporation into sites of prenylation, compatible with downstream processing. Taken together, these data strongly support YnF and YnGG as useful probes for exploring protein prenylation in cells.
The large proportion of substrates detected uniquely by either YnF or YnGG highlights the advantages of a two-probe system to maximize discovery of the prenylated proteome and provides substantially greater coverage than studies using previous probes, which vary probe chain length, introduce hydrophilic linkers and rely on pretreatment with statins to achieve probe incorporation (see Supplementary Table 1 for a comparison with previous probes and studies). These probes cause no overt cytotoxicity and the degree of incorporation is probably modest as a proportion of total prenylated protein, which is probably to minimize the phenotypic effects of probe incorporation; nevertheless, all metabolic labelling approaches involve a perturbation of the biological system. Several of the seven novel farnesylated proteins identified in this study are known to have important biological roles. CEP85 plays a role in controlling centriole duplication 40 , while ULK3 regulates cytokinetic abscission 41 , autophagy and Gli signalling 42 . LRRFIP1, a cytosolic nucleic acid binding protein, is a key mediator of Wnt/ β-catenin signalling 43 . Prenylation data compare favourably with bioinformatic predictions using PrePS 44 , a widely used predictor of non-Rab prenylation motifs, with the majority of experimentally determined substrates predicted to be prenylated by at least one of the prenyl transferase enzymes (Supplementary Data 1) . Conversely, CXXX proteins that did not respond to competition are not predicted substrates, nor do they respond to inhibition by any PTI tested, further suggesting that these proteins (including previously hypothesized substrates UCHL1 and annexin ANXA1) are not prenylated 45 . The present study is the first proteome-scale analysis to identify a large number of prenylated and processed peptides from substrates at endogenous abundance (that is, without substrate overexpression) and the first to demonstrate the compatibility of prenyl probes with the cascade of post-prenylation processing in cells. Furthermore, the novel discovery of C-terminal processing of Rab proteins, which normally carry a double geranylgeranyl CXCX motif (RAB3B, RAB3D and RAB7A), may indicate the existence of a previously unknown mechanism to control prenylation stoichiometry of Rab family members, a phenomenon that merits further investigation. Identification of prenylated peptides is technically challenging for multiple reasons; the high frequency of Arg/ Lys-rich stretches proximal to the prenylation site coupled with post-prenylation processing results in short peptides that have suboptimal chromatographic separation and can be difficult to assign, and this is further compounded by the generally poor ionization of C-terminal tryptic peptides 46 . Identification of an even greater range of modified peptides might be achieved in the future by adaptation of the analytical approach to enhance the detection of short C-terminal tryptic peptides, partially addressed here by the application of lysarginase. We note that the discovery of intact CXXX peptides may be due to the detection of substrates prior to cleavage or native retention of the XXX motif, because recent studies demonstrate that not all prenylated proteins are subject to quantitative processing 47 . Recent reports using protein overexpression and peptide biochemical assays suggest that CXXXX motif proteins may also be substrates for FTase 48 ; we have undertaken careful and detailed inspection of our data in search of CXXXX motif proteins, including both proteomic analyses and direct site identification, but could not find evidence for this non-canonical prenylation motif in this mammalian cell line.
Quantitative analysis of prenylation in response to PTIs demonstrates a range of sensitivity across substrates, which may correspond to differential efficiency of prenylation at each substrate in the complex environment of the cell. Similar nuances have been observed in vitro using peptide substrates (for example, tipifarnib IC 50 of 0.86 nM and 7.9 nM for farnesylation of peptide substrates based on lamin B and KRasB, respectively 31 ), and may influence the mode of action of these compounds in a given disease context. Probes selective towards each transferase enabled the first quantitative whole proteome analysis of the phenomenon of dynamic switching of FTase substrates to prenylation by GGTase-1 in response to FTI treatment, uncovering the novel and intriguing finding that the large majority of substrates show no change in geranylgeranylation at concentrations of tipifarnib sufficient to eliminate FTase activity. The switching propensity of a given protein cannot be reliably predicted based on sequence, and further studies will be required to understand the regulatory mechanisms leading to this surprising result. Although FTI-277 and particularly tipifarnib were confirmed as potent tool inhibitors with excellent selectivity at the whole proteome level, our data provide compelling system-level evidence that any effects on prenylation observed with manumycin A are likely to be due to off-target cytotoxic effects, leading to the conclusion that this compound is ineffective as a chemical probe. Although manumycin A is a weak FTI (IC 50 of 5 µM) and less widely applied than FTI-277 or tipifarnib, it has been used as a tool inhibitor in over 100 previously published studies; we suggest that previous conclusions drawn using manumycin A as an FTI should be treated with caution, unless cross-validated with complementary approaches or more selective tool compounds.
In summary, the novel probes YnF and YnGG provide a unique window onto the prenylated proteome, providing enhanced coverage and selectivity in metabolically active model systems, and complementing in vitro 're-prenylation' approaches 13 . In combination with optimized capture reagents and quantitative proteomic workflows, this method offers a new perspective on prenylation dynamics, prenylated protein processing and inhibitor selectivity, and will be useful for identifying potential novel therapeutic uses for PTIs and for understanding the role and regulation of prenylation in health and disease.
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